HDAC5 Fluorogenic BioAssay™ Kit

Référence 171884-96T

Conditionnement : 96Tests

Marque : US Biological

Demander plus d'informations

Contactez votre distributeur local :


Téléphone : +1 850 650 7790


171884 HDAC5 Fluorogenic BioAssay™ Kit

Clone Type
Polyclonal
Swiss Prot
Q9UQL6
Shipping Temp
Blue Ice
Storage Temp
-20°C/-70°C

The Fluorogenic HDAC5 BioAssay™ Kit is a complete assay system designed to measure histone deacetylase 5 (HDAC5) activity for screening and profiling applications. It comes in a convenient 96-well format, with all the reagents necessary for 100 fluorescent HDAC5 activity measurements. In addition, the kit includes purified HDAC5 enzyme and a potent HDAC inhibitor, Trichostatin A, for use as a positive and negative control. The Fluorogenic HDAC5 Assay Kit is based on a unique fluorogenic substrate and developer combination. This assay method eliminates dealing with the radioactivity, extraction, and chromatography aspects of traditional assays. Using this kit, only two simple steps on a microtiter plate are needed to analyze the HDAC5 activity level. First, the HDAC fluorometric substrate, containing an acetylated lysine side chain, is incubated with purified HDAC5. The deacetylation sensitizes the substrate so subsequent treatment with the Lysine Developer produces a fluorophore that can then be measured using a fluorescence reader. ||COMPONENTS: |HDAC5 human recombinant enzyme, 1x1ug|Fluorogenic HDAC substrate class 2A (5mM), 1x50ul|2x HDAC Developer (contains Trichostatin A) (50um), 1x6ml|Trichostatin A (200um), 1x100ul|HDAC assay buffer, 1x10ml|black, low binding NUNC black microtiter plate, 1 plate||Storage and Stability:|Store powder at 4°C liquid at -20°C. Store other components at 4°C. Stable for at least 6 months For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
References
1. Ontoria, J.M., et al., J. Med. Chem. 2009 Nov 12;52(21):6782-9.